OTCMKTS:ISCOInternational Stem Cell Stock Price, Forecast & News

$0.80

+0.02 (+2.56 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.80

Now: $0.80▼

$0.80

50-Day Range

$0.39

MA: $0.50▼

$0.78

52-Week Range

$0.27

Now: $0.80▼

$1.20

Volume1,432 shs

Average Volume8,669 shs

Market Capitalization$6.03 million

P/E RatioN/A

Dividend YieldN/A

Beta0.9

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for International Stem Cell.

2.5 Community Rank

Outperform Votes
International Stem Cell has received 111 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
International Stem Cell has received 112 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
International Stem Cell has received 50.22% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about International Stem Cell and other stocks. Vote “Outperform” if you believe ISCO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ISCO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
International Stem Cell does not currently pay a dividend.
Dividend Growth
International Stem Cell does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, International Stem Cell insiders have not sold or bought any company stock.
Percentage Held by Insiders
83.16% of the stock of International Stem Cell is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6 Earnings and Valuation

Earnings Growth
Earnings for International Stem Cell are expected to grow in the coming year, from ($1.16) to $0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of International Stem Cell is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of International Stem Cell is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
International Stem Cell has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.83 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:ISCO

Previous Symbol

CUSIP460378102

CIK1355790

Webwww.internationalstemcell.com

Phone760-940-6383

Debt

Debt-to-Equity RatioN/A

Current Ratio0.88

Quick Ratio0.50

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$11.09 million

Price / Sales0.54

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.37 per share

Price / Book2.16

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins-19.28%

Return on Equity-177.87%

Return on Assets-20.54%

Miscellaneous

Employees42

Outstanding Shares7,540,000

Market Cap$6.03 million

Next Earnings Date6/5/2020 (Estimated)

OptionableNot Optionable

Receive ISCO News and Ratings via Email

Sign-up to receive the latest news and ratings for ISCO and its competitors with MarketBeat's FREE daily newsletter.

International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions

How has International Stem Cell's stock been impacted by COVID-19 (Coronavirus)?

International Stem Cell's stock was trading at $0.5850 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ISCO shares have increased by 36.8% and is now trading at $0.80. View which stocks have been most impacted by Coronavirus.

When is International Stem Cell's next earnings date?

International Stem Cell is scheduled to release its next quarterly earnings announcement on Friday, June 5th 2020. View our earnings forecast for International Stem Cell.

How were International Stem Cell's earnings last quarter?

International Stem Cell Corp (OTCMKTS:ISCO) announced its quarterly earnings results on Friday, May, 17th. The biotechnology company reported ($0.12) earnings per share for the quarter. The biotechnology company earned $2.22 million during the quarter. International Stem Cell had a negative net margin of 19.28% and a negative return on equity of 177.87%. View International Stem Cell's earnings history.

Has International Stem Cell been receiving favorable news coverage?

News coverage about ISCO stock has trended somewhat negative on Sunday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. International Stem Cell earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutInternational Stem Cell.

Who are some of International Stem Cell's key competitors?

Some companies that are related to International Stem Cell include Ceapro (CRPOF), Innovate Biopharmaceuticals (INNT), Eyegate Pharmaceuticals (EYEG), AzurRx BioPharma (AZRX), OHR Pharmaceutical (OHRP), Kazia Therapeutics (KZIA), Vistagen Therapeutics (VTGN), Pharmaxis (PXSLY), Teligent (TLGT), Ritter Pharmaceuticals (RTTR), Bio-Path (BPTH), Novus Therapeutics (NVUS), PDS Biotechnology (PDSB), VIVUS (VVUS) and Novan (NOVN). View all competitors.

What other stocks do shareholders of International Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other International Stem Cell investors own include Turkcell Iletisim Hizmetleri A.S. (TKC), Athersys (ATHX), Canopy Growth (CGC), Neuralstem (CUR), Adesto Technologies (IOTS), Biocept (BIOC), FuelCell Energy (FCEL), InterCloud Systems (ICLD), Inpixon (INPX) and Myriad Genetics (MYGN).

Who are International Stem Cell's key executives?

International Stem Cell's management team includes the following people:

Prof. Andrey Semechkin, Co-Chairman & CEO (Age 59)
Dr. Russell Kern, Exec. VP, Chief Scientific Officer & Director (Age 33)
Ms. Sophia Garnette J.D., VP of Legal Affairs & Operations and Sec. (Age 35)
Mr. Francisco Bustamante, Pres of Lifeline Cell Technology LLC

What is International Stem Cell's stock symbol?

International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO."

How do I buy shares of International Stem Cell?

Shares of ISCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is International Stem Cell's stock price today?

One share of ISCO stock can currently be purchased for approximately $0.80.

How big of a company is International Stem Cell?

International Stem Cell has a market capitalization of $6.03 million and generates $11.09 million in revenue each year. International Stem Cell employs 42 workers across the globe.

What is International Stem Cell's official website?

The official website for International Stem Cell is www.internationalstemcell.com.

How can I contact International Stem Cell?

International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at 760-940-6383 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff